New York, November 14, 2016 -- Moody's Investors Service ("Moody's") assigned a rating of A1 to the new senior unsecured note offering of Pfizer Inc. ("Pfizer"). There are no changes to Pfizer's existing ratings and the rating outlook remains stable. Uses of the proceeds include a tender offer for Pfizer's 6.2% senior notes due 2019 as well as general corporate purposes.
Vollständigen Artikel bei Moodys lesen